



FINANCIAL TEAR SHEET

CORPORATE PROFILE

The mission of CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. In addition to our fully-owned programs, we have established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases with high unmet need. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. We are headquartered in Zug, Switzerland with R&D operations in Cambridge, Massachusetts, USA and some business operations in London, United Kingdom.

PRIMARY IR CONTACT

Chris Brinzey
Westwicke Partners
Phone: 339-970-2843
E-mail:
chris.brinzey@westwicke.com

STOCK PERFORMANCE

CRSP (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$18.95**

Change (%) ▼ 0.02 (0.11%)

Volume 168,945

52 Week Low \$11.63


Market Cap \$769,212,128

Rolling EPS -0.07

PE Ratio 0

Shares Outstanding 40,591,669

Data as of 09/25/17 4:00 p.m. ET



RECENT HEADLINES & EVENTS

Aug-22-2017 - 7:30 a.m.
CRISPR Therapeutics Announces Collaboration
with Massachusetts General Hospital to
Research Use of CRISPR/Cas9 in T Cell Cancer
Therapies

There are currently no events scheduled.

Aug-10-2017 - 4:35 p.m.
CRISPR Therapeutics Announces Second
Quarter 2017 Financial Results and Provides
Business Update

Aug-01-2017 - 7:01 a.m.
CRISPR Therapeutics Appoints Dr. Tony W. Ho to
Head Research & Development

SEC FILINGS

Filing Date	Form
09/15/17	SC 13D/A
09/07/17	4
09/07/17	4
09/07/17	4

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources